{"disease":{"id":"dermatitis-atopic","name":"dermatitis atopic"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT03823794","title":"Trends in the Epidemiology and Treatment of Atopic Dermatitis in the United Kingdom (UK)","phase":"","overall_status":"COMPLETED","enrollment_count":148166,"lead_sponsor_name":"Momentum Data","has_results":true},{"nct_id":"NCT03422822","title":"Study to Evaluate Efficacy and Safety of PF-04965842 With or Without Topical Medications in Subjects Aged 12 Years and Older With Moderate to Severe Atopic Dermatitis","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":3166,"lead_sponsor_name":"Pfizer","has_results":false},{"nct_id":"NCT05674695","title":"Spanish Academy of Dermatology and Venereology Registry of Atopic Dermatitis Therapy","phase":"","overall_status":"RECRUITING","enrollment_count":2500,"lead_sponsor_name":"Fundación Academia Española de Dermatología","has_results":false},{"nct_id":"NCT03687359","title":"Observational Evaluation of Atopic Dermatitis in Pediatric Patients","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":1860,"lead_sponsor_name":"Sanofi","has_results":false},{"nct_id":"NCT05492578","title":"Long-Term Safety and Efficacy Evaluation of Amlitelimab in Participants of Previous Amlitelimab Moderate to Severe Atopic Dermatitis Clinical Trials","phase":"PHASE2, PHASE3","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":1663,"lead_sponsor_name":"Sanofi","has_results":false},{"nct_id":"NCT06407934","title":"A Study to Evaluate the Treatment Response and Safety of Two Dose Regimens of Subcutaneous Amlitelimab Compared With Treatment Withdrawal in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":1541,"lead_sponsor_name":"Sanofi","has_results":false},{"nct_id":"NCT03409367","title":"A Community-based Assessment of Skin Care, Allergies, and Eczema","phase":"NA","overall_status":"COMPLETED","enrollment_count":1260,"lead_sponsor_name":"Oregon Health and Science University","has_results":true},{"nct_id":"NCT03627767","title":"Study to Investigate Efficacy and Safety of PF-04965842 in Subjects Aged 12 Years and Over With Moderate to Severe Atopic Dermatitis With the Option of Rescue Treatment in Flaring Subjects","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":1235,"lead_sponsor_name":"Pfizer","has_results":true},{"nct_id":"NCT05177744","title":"Toxicity of Micro and Nano Plastics Combined With Environmental Contaminants on the Risk of Allergic Disease","phase":"","overall_status":"COMPLETED","enrollment_count":1156,"lead_sponsor_name":"Children's Hospital Srebrnjak","has_results":false},{"nct_id":"NCT05391061","title":"A Study to Learn About the Study Medicine (Called Cibinqo) in People With Atopic Dermatitis","phase":"","overall_status":"RECRUITING","enrollment_count":1100,"lead_sponsor_name":"Pfizer","has_results":false},{"nct_id":"NCT04240522","title":"Prospective Longitudinal Observational Research in Atopic Dermatitis","phase":"","overall_status":"RECRUITING","enrollment_count":1000,"lead_sponsor_name":"University of Zurich","has_results":false},{"nct_id":"NCT03992417","title":"Observational Study of Patients Receiving Dupixent® for Atopic Dermatitis (AD)","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":955,"lead_sponsor_name":"Sanofi","has_results":false},{"nct_id":"NCT05769777","title":"Open Label, Long-term Study Evaluating Safety and Efficacy of Subcutaneous Amlitelimab in Participants Aged 12 Years and Older With Moderate to Severe Atopic Dermatitis","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":901,"lead_sponsor_name":"Sanofi","has_results":false},{"nct_id":"NCT03428646","title":"Study of Patients Receiving DUPIXENT® for Atopic Dermatitis (AD)","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":858,"lead_sponsor_name":"Regeneron Pharmaceuticals","has_results":false},{"nct_id":"NCT03720470","title":"Study Evaluating Efficacy and Safety of PF-04965842 and Dupilumab in Adult Subjects With Moderate to Severe Atopic Dermatitis on Background Topical Therapy","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":838,"lead_sponsor_name":"Pfizer","has_results":true},{"nct_id":"NCT02277769","title":"Study of Dupilumab (REGN668/SAR231893) Monotherapy Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":708,"lead_sponsor_name":"Regeneron Pharmaceuticals","has_results":true},{"nct_id":"NCT06224348","title":"A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis on Background Topical Corticosteroids","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":643,"lead_sponsor_name":"Sanofi","has_results":false},{"nct_id":"NCT06241118","title":"A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab on Background Topical Corticosteroids Therapy in Participants Aged 12 Years and Older With Moderate-to-severe AD Who Have Had an Inadequate Response to Prior Biologic Therapy or an Oral JAK Inhibitor","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":636,"lead_sponsor_name":"Sanofi","has_results":false},{"nct_id":"NCT06130566","title":"A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab Monotherapy Compared With Placebo in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":601,"lead_sponsor_name":"Sanofi","has_results":false},{"nct_id":"NCT06181435","title":"A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab Monotherapy Compared With Placebo in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis (COAST 2)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":589,"lead_sponsor_name":"Sanofi","has_results":false},{"nct_id":"NCT06173284","title":"Evaluation of 611(Recombinant Humanized Anti-interleukin-4 Receptor Alpha IgG4 Monoclonal Antibody) in Chinese Adults With Moderate to Severe Atopic Dermatitis","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":519,"lead_sponsor_name":"Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.","has_results":false},{"nct_id":"NCT00152464","title":"Prevention of Asthma With Levocetirizine 18 Month Treatment in Infants (12 - 24 Months) Suffering From Eczema (Atopic Dermatitis) and Sensitized to Grass Pollen and/or House Dust Mite (HDM)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":514,"lead_sponsor_name":"UCB Pharma SA","has_results":true},{"nct_id":"NCT06554847","title":"Evaluation of 611 in Combination With Topical Corticosteroid in Participants With Moderate to Severe Atopic Dermatitis","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":400,"lead_sponsor_name":"Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.","has_results":false},{"nct_id":"NCT03742414","title":"Seal, Stopping Eczema and Allergy Study","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":398,"lead_sponsor_name":"Kari Nadeau, MD, PhD","has_results":false},{"nct_id":"NCT03575871","title":"Study Evaluating Efficacy and Safety of PF-04965842 in Subjects Aged 12 Years And Older With Moderate to Severe Atopic Dermatitis","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":391,"lead_sponsor_name":"Pfizer","has_results":true},{"nct_id":"NCT03349060","title":"Study to Evaluate Efficacy and Safety of PF-04965842 in Subjects Aged 12 Years And Older With Moderate to Severe Atopic Dermatitis","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":387,"lead_sponsor_name":"Pfizer","has_results":true},{"nct_id":"NCT03345914","title":"Study to Investigate the Efficacy and Safety of Dupilumab Administered With Topical Corticosteroids (TCS) in Participants ≥6 to <12 Years With Severe Atopic Dermatitis (AD)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":367,"lead_sponsor_name":"Regeneron Pharmaceuticals","has_results":true},{"nct_id":"NCT05149313","title":"A Study of Lebrikizumab in Combination With Topical Corticosteroids in Patients With Atopic Dermatitis (AD) That Are Not Adequately Controlled With or Are Non-eligible for Cyclosporine","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":331,"lead_sponsor_name":"Almirall, S.A.","has_results":true},{"nct_id":"NCT04878770","title":"NMF-CsA-Dupi Trial","phase":"NA","overall_status":"UNKNOWN","enrollment_count":318,"lead_sponsor_name":"Erasmus Medical Center","has_results":false},{"nct_id":"NCT06747897","title":"An Observational Study to Gather Real-World User Feedback on DIPROBASE® Advanced Eczema Cream in Adults and Children With Eczema or Dry Skin","phase":"","overall_status":"COMPLETED","enrollment_count":300,"lead_sponsor_name":"Bayer","has_results":false},{"nct_id":"NCT03928431","title":"Restoration of Microbiota in Neonates","phase":"NA","overall_status":"RECRUITING","enrollment_count":300,"lead_sponsor_name":"Karolinska Institutet","has_results":false},{"nct_id":"NCT05078294","title":"Results in Real Clinical Practice of Treatment of Moderate-severe Atopic Dermatitis","phase":"","overall_status":"UNKNOWN","enrollment_count":300,"lead_sponsor_name":"Fundación Pública Andaluza para la gestión de la Investigación en Sevilla","has_results":false},{"nct_id":"NCT03981926","title":"Team-Based Connected Health (TCH) to Improve Clinical Outcomes and Access in Atopic Dermatitis","phase":"NA","overall_status":"COMPLETED","enrollment_count":300,"lead_sponsor_name":"University of Southern California","has_results":true},{"nct_id":"NCT04760314","title":"A Study of Lebrikizumab (LY3650150) in Combination With Topical Corticosteroids in Japanese Participants With Moderate-to-Severe Atopic Dermatitis","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":286,"lead_sponsor_name":"Eli Lilly and Company","has_results":true},{"nct_id":"NCT07438509","title":"Efficacy of Crisaborole 2% Cream Versus Placebo in Mild to Moderate Atopic Eczema","phase":"PHASE4","overall_status":"NOT_YET_RECRUITING","enrollment_count":270,"lead_sponsor_name":"Jinnah Postgraduate Medical Centre","has_results":false},{"nct_id":"NCT03849716","title":"Evaluation of Biomarkers of Atopic Dermatitis in Pediatric Patients (PEDISTAD BIOMARKER STUDY)","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":266,"lead_sponsor_name":"Sanofi","has_results":false},{"nct_id":"NCT05642208","title":"Dupilumab Step-down Strategy to Maintain Remission in Adult and Adolescents Patients With Atopic Dermatitis","phase":"PHASE4","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":256,"lead_sponsor_name":"Nantes University Hospital","has_results":false},{"nct_id":"NCT06881251","title":"A Study of JNJ-95475939 in the Treatment of Participants With Moderate to Severe Atopic Dermatitis (AD)","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":256,"lead_sponsor_name":"Janssen Research & Development, LLC","has_results":false},{"nct_id":"NCT03054428","title":"Efficacy and Safety of Dupilumab in Participants ≥12 to <18 Years of Age, With Moderate-to-severe Atopic Dermatitis","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":251,"lead_sponsor_name":"Regeneron Pharmaceuticals","has_results":true},{"nct_id":"NCT04684485","title":"To Assess the Efficacy and Safety of SCD-044 in the Treatment of Moderate to Severe Atopic Dermatitis","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":250,"lead_sponsor_name":"Sun Pharmaceutical Industries Limited","has_results":true},{"nct_id":"NCT02564055","title":"A Dose-Finding Study of GSK2894512 Cream in Subjects With Atopic Dermatitis (AD)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":247,"lead_sponsor_name":"GlaxoSmithKline","has_results":true},{"nct_id":"NCT03722706","title":"Improving Therapeutic Patient Education for Atopic Dermatitis: Evaluation of a Parent Handbook","phase":"NA","overall_status":"COMPLETED","enrollment_count":246,"lead_sponsor_name":"Boston Children's Hospital","has_results":false},{"nct_id":"NCT04365387","title":"A Study to Assess Immunization Responses in Adult and Adolescent Participants With Moderate-to-Severe Atopic Dermatitis Treated With Nemolizumab","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":242,"lead_sponsor_name":"Galderma R&D","has_results":true},{"nct_id":"NCT05958407","title":"A 32-week Trial to Evaluate the Efficacy and Safety of Tralokinumab in Subjects With Moderate-to-severe Atopic Hand Eczema Who Are Candidates for Systemic Therapy","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":235,"lead_sponsor_name":"LEO Pharma","has_results":false},{"nct_id":"NCT06015308","title":"A Study to Investigate Vaccine Responses in Subcutaneous Amlitelimab Treated Atopic Dermatitis Participants Aged 18 Years and Older Compared With Placebo","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":224,"lead_sponsor_name":"Sanofi","has_results":false},{"nct_id":"NCT05899816","title":"A Study Assessing Rocatinlimab on Vaccine Antibody Response in Moderate-to-severe Atopic Dermatitis (AD) (ROCKET - VOYAGER)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":221,"lead_sponsor_name":"Amgen","has_results":false},{"nct_id":"NCT04800315","title":"A Study to Evaluate Safety and Effectiveness of Cendakimab (CC-93538) in Participants With Moderate to Severe Atopic Dermatitis","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":221,"lead_sponsor_name":"Celgene","has_results":true},{"nct_id":"NCT06004986","title":"DUPIlumab Dose REDUCtion in Patients With Controlled Atopic Eczema","phase":"PHASE4","overall_status":"RECRUITING","enrollment_count":216,"lead_sponsor_name":"Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)","has_results":false},{"nct_id":"NCT06024499","title":"Phase 2 Trial of HY209gel in Atopic Dermatitis Patients","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":210,"lead_sponsor_name":"Shaperon","has_results":false},{"nct_id":"NCT03175354","title":"A Study in Subjects With Moderate Atopic Dermatitis","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":209,"lead_sponsor_name":"Ralexar Therapeutics, Inc.","has_results":false}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}